We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 40.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSCI
26
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$29.3M 0.24%
3,457,841
-79,296
-2% -$675K
PGNX
27
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$26M 0.22%
4,350,808
-98,989
-2% -$623K
ACGN
28
DELISTED
Aceragen Inc
ACGN
$25.8M 0.21%
51,268
+39,284
+328% +$24M
ALDR
29
DELISTED
Alder Biopharmaceuticals
ALDR
$25.4M 0.21%
879,581
+726,231
+474% +$19.9M
ACOR
30
DELISTED
Acorda Therapeutics
ACOR
$24.6M 0.2%
6,158
-138
-2% -$632K
GILD icon
31
Gilead Sciences
GILD
$167B
$24.5M 0.2%
249,995
-6,113
-2% -$621K
SGMO
32
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$22M 0.18%
1,404,544
+449,212
+47% +$6.95M
NBIX icon
33
Neurocrine Biosciences
NBIX
$18.3B
$21.5M 0.18%
542,236
-12,354
-2% -$442K
KYTH
34
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$17.8M 0.15%
354,265
+68,010
+24% +$2.85M
BLUE
35
DELISTED
bluebird bio
BLUE
$17.7M 0.15%
11,316
-264
-2% -$348K
RPRX
36
DELISTED
Repros Therapeutics Inc.
RPRX
$17.2M 0.14%
2,000,000
– –
FOMX
37
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$16.9M 0.14%
1,821,967
+800,367
+78% +$7.16M
VNDA icon
38
Vanda Pharmaceuticals
VNDA
$298M
$16.3M 0.14%
1,750,230
-2,721,923
-61% -$30.8M
NVAX icon
39
Novavax
NVAX
$1.22B
$16.1M 0.13%
97,284
+36,116
+59% +$5.86M
IOVA icon
40
Iovance Biotherapeutics
IOVA
$2.08B
$16M 0.13%
+1,325,000
New +$14.9M
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
$15M 0.13%
202,630
– –
AGIO icon
42
Agios Pharmaceuticals
AGIO
$2.1B
$14.1M 0.12%
149,954
-13,439
-8% -$1.51M
OMER icon
43
Omeros
OMER
$838M
$14M 0.12%
637,446
-10,655
-2% -$243K
XNCR icon
44
Xencor
XNCR
$1.47B
$13.4M 0.11%
872,072
+280,701
+47% +$4.43M
MTEM
45
DELISTED
Molecular Templates, Inc.
MTEM
$11.9M 0.1%
17,730
+4,666
+36% +$3.07M
ARCT icon
46
Arcturus Therapeutics
ARCT
$162M
$10.1M 0.08%
255,696
+214,286
+517% +$9.43M
NGNE icon
47
Neurogene
NGNE
$656M
$9.76M 0.08%
59,383
-1,135
-2% -$231K
MGNX icon
48
MacroGenics
MGNX
$238M
$9.57M 0.08%
305,043
-6,848
-2% -$232K
AERI
49
DELISTED
Aerie Pharmaceuticals
AERI
$9.38M 0.08%
299,356
– –
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.5B
$9.24M 0.08%
148,894
-1,106
-0.7% -$61.4K
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Baker Bros. Advisors held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Invitae Corporation worth $110M.

  • Baker Bros. Advisors's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Baker Bros. Advisors fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Baker Bros. Advisors opened 18 new positions and closed 10 in Q1 2015.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.